Z-100, Extracted from Mycobacterium tuberculosis Strain Aoyama B, Inhibits the Development of Collagen-Induced Arthritis in Mice
We evaluated the effects of Z-100, extracted from human type Mycobacterium tuberculosis strain Aoyama B, on collagen-induced arthritis (CIA) in mice. One hundred thirty-five DBA-1K mice, 8 weeks of age, were assigned to 9 groups and immunized with bovine type II collagen (CII) or CFA. From the next...
Gespeichert in:
Veröffentlicht in: | Biological & pharmaceutical bulletin 1997/06/15, Vol.20(6), pp.694-697 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 697 |
---|---|
container_issue | 6 |
container_start_page | 694 |
container_title | Biological & pharmaceutical bulletin |
container_volume | 20 |
creator | OMATA, Takeshi SEGAWA, Yoshihide TAMAKI, Hajime FUJISAKU, Atsushi KOIKE, Takao |
description | We evaluated the effects of Z-100, extracted from human type Mycobacterium tuberculosis strain Aoyama B, on collagen-induced arthritis (CIA) in mice. One hundred thirty-five DBA-1K mice, 8 weeks of age, were assigned to 9 groups and immunized with bovine type II collagen (CII) or CFA. From the next day, Z-100 at does of 0.004, 0.04 or 0.4 mg/kg B.W./d for 48 d was intradermally injected into the tail base. Methotrexate (MTX) at daily doses of 0.1, 0.3, or 1.0 mg/kg B.W. and cyclophosphamide (CY) and at a daily dose of 5 mg/kg. B.W. were used as reference drugs. The effects of these drugs on CIA mice were evaluated in terms of the incidence of CIA, the arthritis index (AI), and hind paw edema, after which the animals were sacrificed at 49 d, and both anti-CII antibody titer and delayed-type hypersensitivity (DTH) reaction were measured. In the arthritic control groups, the AI and hind paw edema were significantly increased after the second immunization on day 28. The anti-CII antibody titer and DTH reaction were significantly increased compared to normal mice on day 49. Z-100 significantly inhibited the AI at a dose of 0.4 mg/kg/d on day 49, and suppressed the incidence of both CIA and hind paw edema. Increases in both anti-CII antibody titer and DTH reaction in CIA mice were prevented by treatment with Z-100 at 0.4 mg/kg/d. MTX, in a dose-dependent manner, and CY, at a dose of 5 mg/kg/d, inhibited the incidence of CIA, AI hind paw edema, anti-CII antibody titer and DTH reaction in CIA mice. Z-100 at a dose of 0.4 mg/kg was as effective as MTX was at a dose of 0.3 mg/kg against the DTH reaction, and it had no side effects. These results suggest the usefulness of Z-100 in patients with chronic rheumatoid arthritis. |
doi_str_mv | 10.1248/bpb.20.694 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_16081167</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>16081167</sourcerecordid><originalsourceid>FETCH-LOGICAL-c658t-23a0126ed6acba1a2ef4a0d406136bf1ad86059b2239e37351dd283a80653ba93</originalsourceid><addsrcrecordid>eNpdkb2PEzEUxC0EOsJBQ49kCUSBboM_dr3rMoQDIt2JAmhoLNv7ljjatYPtRaTjT8chUQoaW9b8NPOeB6HnlCwpq7u3Zm-WjCyFrB-gBeV1WzWMNg_RgkjaVYI23WP0JKUdIaQljF-hK8kok5Iv0J_vFSXkBt_-zlHbDD0eYpjw_cEGc3xHN084zwainceQXMJfCug8XoWDnjR-d4M3fuuMywnnLeD38AvGsJ_AZxwGvA7jqH-Arza-n21xX8W8jS4Xn-Jx7yw8RY8GPSZ4dr6v0bcPt1_Xn6q7zx8369VdZUXT5YpxTSgT0AttjaaawVBr0tdEUC7MQHXfCdJIwxiXwFve0L5nHdcdEQ03WvJr9Prku4_h5wwpq8klC2U8D2FOigrSUSraAr78D9yFOfoym6J1LQsi2yP15kTZGFKKMKh9dJOOB0WJOpaiSimKEVVKKfCLs-VsJugv6LmFor866zpZPQ5Re-vSBWNtWbLpCrY-YbuUy6dedB2zsyMcE2mx-5d6Okr4RbVbHRV4_hfHmasy</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1449167977</pqid></control><display><type>article</type><title>Z-100, Extracted from Mycobacterium tuberculosis Strain Aoyama B, Inhibits the Development of Collagen-Induced Arthritis in Mice</title><source>J-STAGE Free</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Free Full-Text Journals in Chemistry</source><creator>OMATA, Takeshi ; SEGAWA, Yoshihide ; TAMAKI, Hajime ; FUJISAKU, Atsushi ; KOIKE, Takao</creator><creatorcontrib>OMATA, Takeshi ; SEGAWA, Yoshihide ; TAMAKI, Hajime ; FUJISAKU, Atsushi ; KOIKE, Takao</creatorcontrib><description>We evaluated the effects of Z-100, extracted from human type Mycobacterium tuberculosis strain Aoyama B, on collagen-induced arthritis (CIA) in mice. One hundred thirty-five DBA-1K mice, 8 weeks of age, were assigned to 9 groups and immunized with bovine type II collagen (CII) or CFA. From the next day, Z-100 at does of 0.004, 0.04 or 0.4 mg/kg B.W./d for 48 d was intradermally injected into the tail base. Methotrexate (MTX) at daily doses of 0.1, 0.3, or 1.0 mg/kg B.W. and cyclophosphamide (CY) and at a daily dose of 5 mg/kg. B.W. were used as reference drugs. The effects of these drugs on CIA mice were evaluated in terms of the incidence of CIA, the arthritis index (AI), and hind paw edema, after which the animals were sacrificed at 49 d, and both anti-CII antibody titer and delayed-type hypersensitivity (DTH) reaction were measured. In the arthritic control groups, the AI and hind paw edema were significantly increased after the second immunization on day 28. The anti-CII antibody titer and DTH reaction were significantly increased compared to normal mice on day 49. Z-100 significantly inhibited the AI at a dose of 0.4 mg/kg/d on day 49, and suppressed the incidence of both CIA and hind paw edema. Increases in both anti-CII antibody titer and DTH reaction in CIA mice were prevented by treatment with Z-100 at 0.4 mg/kg/d. MTX, in a dose-dependent manner, and CY, at a dose of 5 mg/kg/d, inhibited the incidence of CIA, AI hind paw edema, anti-CII antibody titer and DTH reaction in CIA mice. Z-100 at a dose of 0.4 mg/kg was as effective as MTX was at a dose of 0.3 mg/kg against the DTH reaction, and it had no side effects. These results suggest the usefulness of Z-100 in patients with chronic rheumatoid arthritis.</description><identifier>ISSN: 0918-6158</identifier><identifier>EISSN: 1347-5215</identifier><identifier>DOI: 10.1248/bpb.20.694</identifier><identifier>PMID: 9212993</identifier><language>eng</language><publisher>Tokyo: The Pharmaceutical Society of Japan</publisher><subject>Adjuvants, Immunologic - isolation & purification ; Adjuvants, Immunologic - pharmacology ; Animals ; Antibodies - blood ; Antibodies - immunology ; Antirheumatic Agents - isolation & purification ; Antirheumatic Agents - pharmacology ; Arthritis, Experimental - immunology ; Arthritis, Experimental - pathology ; Arthritis, Experimental - prevention & control ; Biological and medical sciences ; Collagen - immunology ; collagen-induced arthritis ; Cyclophosphamide - pharmacology ; Diseases of the osteoarticular system ; Hindlimb ; Hypersensitivity, Delayed - immunology ; Immunomodulators ; Immunosuppressive Agents - pharmacology ; Inflammatory joint diseases ; Lipids - isolation & purification ; Lipids - pharmacology ; Male ; Mannans - isolation & purification ; Mannans - pharmacology ; Medical sciences ; methotrexate ; Methotrexate - pharmacology ; Mice ; Mice, Inbred DBA ; Mycobacterium tuberculosis ; Mycobacterium tuberculosis - chemistry ; Pharmacology. Drug treatments ; Severity of Illness Index ; Z-100</subject><ispartof>Biological and Pharmaceutical Bulletin, 1997/06/15, Vol.20(6), pp.694-697</ispartof><rights>The Pharmaceutical Society of Japan</rights><rights>1997 INIST-CNRS</rights><rights>Copyright Japan Science and Technology Agency 1997</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c658t-23a0126ed6acba1a2ef4a0d406136bf1ad86059b2239e37351dd283a80653ba93</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,1877,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2761358$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9212993$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>OMATA, Takeshi</creatorcontrib><creatorcontrib>SEGAWA, Yoshihide</creatorcontrib><creatorcontrib>TAMAKI, Hajime</creatorcontrib><creatorcontrib>FUJISAKU, Atsushi</creatorcontrib><creatorcontrib>KOIKE, Takao</creatorcontrib><title>Z-100, Extracted from Mycobacterium tuberculosis Strain Aoyama B, Inhibits the Development of Collagen-Induced Arthritis in Mice</title><title>Biological & pharmaceutical bulletin</title><addtitle>Biol Pharm Bull</addtitle><description>We evaluated the effects of Z-100, extracted from human type Mycobacterium tuberculosis strain Aoyama B, on collagen-induced arthritis (CIA) in mice. One hundred thirty-five DBA-1K mice, 8 weeks of age, were assigned to 9 groups and immunized with bovine type II collagen (CII) or CFA. From the next day, Z-100 at does of 0.004, 0.04 or 0.4 mg/kg B.W./d for 48 d was intradermally injected into the tail base. Methotrexate (MTX) at daily doses of 0.1, 0.3, or 1.0 mg/kg B.W. and cyclophosphamide (CY) and at a daily dose of 5 mg/kg. B.W. were used as reference drugs. The effects of these drugs on CIA mice were evaluated in terms of the incidence of CIA, the arthritis index (AI), and hind paw edema, after which the animals were sacrificed at 49 d, and both anti-CII antibody titer and delayed-type hypersensitivity (DTH) reaction were measured. In the arthritic control groups, the AI and hind paw edema were significantly increased after the second immunization on day 28. The anti-CII antibody titer and DTH reaction were significantly increased compared to normal mice on day 49. Z-100 significantly inhibited the AI at a dose of 0.4 mg/kg/d on day 49, and suppressed the incidence of both CIA and hind paw edema. Increases in both anti-CII antibody titer and DTH reaction in CIA mice were prevented by treatment with Z-100 at 0.4 mg/kg/d. MTX, in a dose-dependent manner, and CY, at a dose of 5 mg/kg/d, inhibited the incidence of CIA, AI hind paw edema, anti-CII antibody titer and DTH reaction in CIA mice. Z-100 at a dose of 0.4 mg/kg was as effective as MTX was at a dose of 0.3 mg/kg against the DTH reaction, and it had no side effects. These results suggest the usefulness of Z-100 in patients with chronic rheumatoid arthritis.</description><subject>Adjuvants, Immunologic - isolation & purification</subject><subject>Adjuvants, Immunologic - pharmacology</subject><subject>Animals</subject><subject>Antibodies - blood</subject><subject>Antibodies - immunology</subject><subject>Antirheumatic Agents - isolation & purification</subject><subject>Antirheumatic Agents - pharmacology</subject><subject>Arthritis, Experimental - immunology</subject><subject>Arthritis, Experimental - pathology</subject><subject>Arthritis, Experimental - prevention & control</subject><subject>Biological and medical sciences</subject><subject>Collagen - immunology</subject><subject>collagen-induced arthritis</subject><subject>Cyclophosphamide - pharmacology</subject><subject>Diseases of the osteoarticular system</subject><subject>Hindlimb</subject><subject>Hypersensitivity, Delayed - immunology</subject><subject>Immunomodulators</subject><subject>Immunosuppressive Agents - pharmacology</subject><subject>Inflammatory joint diseases</subject><subject>Lipids - isolation & purification</subject><subject>Lipids - pharmacology</subject><subject>Male</subject><subject>Mannans - isolation & purification</subject><subject>Mannans - pharmacology</subject><subject>Medical sciences</subject><subject>methotrexate</subject><subject>Methotrexate - pharmacology</subject><subject>Mice</subject><subject>Mice, Inbred DBA</subject><subject>Mycobacterium tuberculosis</subject><subject>Mycobacterium tuberculosis - chemistry</subject><subject>Pharmacology. Drug treatments</subject><subject>Severity of Illness Index</subject><subject>Z-100</subject><issn>0918-6158</issn><issn>1347-5215</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkb2PEzEUxC0EOsJBQ49kCUSBboM_dr3rMoQDIt2JAmhoLNv7ljjatYPtRaTjT8chUQoaW9b8NPOeB6HnlCwpq7u3Zm-WjCyFrB-gBeV1WzWMNg_RgkjaVYI23WP0JKUdIaQljF-hK8kok5Iv0J_vFSXkBt_-zlHbDD0eYpjw_cEGc3xHN084zwainceQXMJfCug8XoWDnjR-d4M3fuuMywnnLeD38AvGsJ_AZxwGvA7jqH-Arza-n21xX8W8jS4Xn-Jx7yw8RY8GPSZ4dr6v0bcPt1_Xn6q7zx8369VdZUXT5YpxTSgT0AttjaaawVBr0tdEUC7MQHXfCdJIwxiXwFve0L5nHdcdEQ03WvJr9Prku4_h5wwpq8klC2U8D2FOigrSUSraAr78D9yFOfoym6J1LQsi2yP15kTZGFKKMKh9dJOOB0WJOpaiSimKEVVKKfCLs-VsJugv6LmFor866zpZPQ5Re-vSBWNtWbLpCrY-YbuUy6dedB2zsyMcE2mx-5d6Okr4RbVbHRV4_hfHmasy</recordid><startdate>19970601</startdate><enddate>19970601</enddate><creator>OMATA, Takeshi</creator><creator>SEGAWA, Yoshihide</creator><creator>TAMAKI, Hajime</creator><creator>FUJISAKU, Atsushi</creator><creator>KOIKE, Takao</creator><general>The Pharmaceutical Society of Japan</general><general>Maruzen</general><general>Japan Science and Technology Agency</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7QL</scope><scope>C1K</scope></search><sort><creationdate>19970601</creationdate><title>Z-100, Extracted from Mycobacterium tuberculosis Strain Aoyama B, Inhibits the Development of Collagen-Induced Arthritis in Mice</title><author>OMATA, Takeshi ; SEGAWA, Yoshihide ; TAMAKI, Hajime ; FUJISAKU, Atsushi ; KOIKE, Takao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c658t-23a0126ed6acba1a2ef4a0d406136bf1ad86059b2239e37351dd283a80653ba93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Adjuvants, Immunologic - isolation & purification</topic><topic>Adjuvants, Immunologic - pharmacology</topic><topic>Animals</topic><topic>Antibodies - blood</topic><topic>Antibodies - immunology</topic><topic>Antirheumatic Agents - isolation & purification</topic><topic>Antirheumatic Agents - pharmacology</topic><topic>Arthritis, Experimental - immunology</topic><topic>Arthritis, Experimental - pathology</topic><topic>Arthritis, Experimental - prevention & control</topic><topic>Biological and medical sciences</topic><topic>Collagen - immunology</topic><topic>collagen-induced arthritis</topic><topic>Cyclophosphamide - pharmacology</topic><topic>Diseases of the osteoarticular system</topic><topic>Hindlimb</topic><topic>Hypersensitivity, Delayed - immunology</topic><topic>Immunomodulators</topic><topic>Immunosuppressive Agents - pharmacology</topic><topic>Inflammatory joint diseases</topic><topic>Lipids - isolation & purification</topic><topic>Lipids - pharmacology</topic><topic>Male</topic><topic>Mannans - isolation & purification</topic><topic>Mannans - pharmacology</topic><topic>Medical sciences</topic><topic>methotrexate</topic><topic>Methotrexate - pharmacology</topic><topic>Mice</topic><topic>Mice, Inbred DBA</topic><topic>Mycobacterium tuberculosis</topic><topic>Mycobacterium tuberculosis - chemistry</topic><topic>Pharmacology. Drug treatments</topic><topic>Severity of Illness Index</topic><topic>Z-100</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>OMATA, Takeshi</creatorcontrib><creatorcontrib>SEGAWA, Yoshihide</creatorcontrib><creatorcontrib>TAMAKI, Hajime</creatorcontrib><creatorcontrib>FUJISAKU, Atsushi</creatorcontrib><creatorcontrib>KOIKE, Takao</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Biological & pharmaceutical bulletin</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>OMATA, Takeshi</au><au>SEGAWA, Yoshihide</au><au>TAMAKI, Hajime</au><au>FUJISAKU, Atsushi</au><au>KOIKE, Takao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Z-100, Extracted from Mycobacterium tuberculosis Strain Aoyama B, Inhibits the Development of Collagen-Induced Arthritis in Mice</atitle><jtitle>Biological & pharmaceutical bulletin</jtitle><addtitle>Biol Pharm Bull</addtitle><date>1997-06-01</date><risdate>1997</risdate><volume>20</volume><issue>6</issue><spage>694</spage><epage>697</epage><pages>694-697</pages><issn>0918-6158</issn><eissn>1347-5215</eissn><abstract>We evaluated the effects of Z-100, extracted from human type Mycobacterium tuberculosis strain Aoyama B, on collagen-induced arthritis (CIA) in mice. One hundred thirty-five DBA-1K mice, 8 weeks of age, were assigned to 9 groups and immunized with bovine type II collagen (CII) or CFA. From the next day, Z-100 at does of 0.004, 0.04 or 0.4 mg/kg B.W./d for 48 d was intradermally injected into the tail base. Methotrexate (MTX) at daily doses of 0.1, 0.3, or 1.0 mg/kg B.W. and cyclophosphamide (CY) and at a daily dose of 5 mg/kg. B.W. were used as reference drugs. The effects of these drugs on CIA mice were evaluated in terms of the incidence of CIA, the arthritis index (AI), and hind paw edema, after which the animals were sacrificed at 49 d, and both anti-CII antibody titer and delayed-type hypersensitivity (DTH) reaction were measured. In the arthritic control groups, the AI and hind paw edema were significantly increased after the second immunization on day 28. The anti-CII antibody titer and DTH reaction were significantly increased compared to normal mice on day 49. Z-100 significantly inhibited the AI at a dose of 0.4 mg/kg/d on day 49, and suppressed the incidence of both CIA and hind paw edema. Increases in both anti-CII antibody titer and DTH reaction in CIA mice were prevented by treatment with Z-100 at 0.4 mg/kg/d. MTX, in a dose-dependent manner, and CY, at a dose of 5 mg/kg/d, inhibited the incidence of CIA, AI hind paw edema, anti-CII antibody titer and DTH reaction in CIA mice. Z-100 at a dose of 0.4 mg/kg was as effective as MTX was at a dose of 0.3 mg/kg against the DTH reaction, and it had no side effects. These results suggest the usefulness of Z-100 in patients with chronic rheumatoid arthritis.</abstract><cop>Tokyo</cop><pub>The Pharmaceutical Society of Japan</pub><pmid>9212993</pmid><doi>10.1248/bpb.20.694</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0918-6158 |
ispartof | Biological and Pharmaceutical Bulletin, 1997/06/15, Vol.20(6), pp.694-697 |
issn | 0918-6158 1347-5215 |
language | eng |
recordid | cdi_proquest_miscellaneous_16081167 |
source | J-STAGE Free; MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Free Full-Text Journals in Chemistry |
subjects | Adjuvants, Immunologic - isolation & purification Adjuvants, Immunologic - pharmacology Animals Antibodies - blood Antibodies - immunology Antirheumatic Agents - isolation & purification Antirheumatic Agents - pharmacology Arthritis, Experimental - immunology Arthritis, Experimental - pathology Arthritis, Experimental - prevention & control Biological and medical sciences Collagen - immunology collagen-induced arthritis Cyclophosphamide - pharmacology Diseases of the osteoarticular system Hindlimb Hypersensitivity, Delayed - immunology Immunomodulators Immunosuppressive Agents - pharmacology Inflammatory joint diseases Lipids - isolation & purification Lipids - pharmacology Male Mannans - isolation & purification Mannans - pharmacology Medical sciences methotrexate Methotrexate - pharmacology Mice Mice, Inbred DBA Mycobacterium tuberculosis Mycobacterium tuberculosis - chemistry Pharmacology. Drug treatments Severity of Illness Index Z-100 |
title | Z-100, Extracted from Mycobacterium tuberculosis Strain Aoyama B, Inhibits the Development of Collagen-Induced Arthritis in Mice |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T01%3A03%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Z-100,%20Extracted%20from%20Mycobacterium%20tuberculosis%20Strain%20Aoyama%20B,%20Inhibits%20the%20Development%20of%20Collagen-Induced%20Arthritis%20in%20Mice&rft.jtitle=Biological%20&%20pharmaceutical%20bulletin&rft.au=OMATA,%20Takeshi&rft.date=1997-06-01&rft.volume=20&rft.issue=6&rft.spage=694&rft.epage=697&rft.pages=694-697&rft.issn=0918-6158&rft.eissn=1347-5215&rft_id=info:doi/10.1248/bpb.20.694&rft_dat=%3Cproquest_cross%3E16081167%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1449167977&rft_id=info:pmid/9212993&rfr_iscdi=true |